Development
Cytokinetics, Incorporated
CYTK
$35.14
-$1.02-2.82%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -5.77% | -0.61% | 2.02% | 4.43% | 3.46% |
| Total Depreciation and Amortization | 241.69% | -0.05% | 0.38% | 11.46% | 17.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.03% | 2.77% | 10.44% | 27.23% | -54.15% |
| Change in Net Operating Assets | 2,930.32% | 106.15% | -25.70% | -213.85% | 43.55% |
| Cash from Operations | 23.04% | 21.02% | 0.39% | -24.54% | -16.84% |
| Capital Expenditure | 65.00% | 69.32% | -78.36% | 87.46% | 49.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -211.02% | -11.57% | -50.06% | 411.18% | 111.35% |
| Cash from Investing | -211.46% | -11.07% | -50.37% | 465.82% | 110.00% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -2.30% | -2.36% | -2.42% | -97.14% | 99.93% |
| Issuance of Common Stock | 3,710.23% | -22.00% | 60.33% | -1.42% | -41.85% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | 211.33% | 890.30% | 176.29% | -124.02% | -92.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.07% | 190.79% | -194.92% | 192.26% | -409.80% |